# 2026-19654: Doc Aslam booted forever from FDA drug dealings 2026-19654, Naveed Aslam: Final Debarment Order, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-09-25, effective 2026-09-25; PRIA reads it as touching household money (as of 2026-10-02). - Canonical: https://policyrisk.com/federal-register/2026-19654 - As of: 2026-10-02 - Plain-text twin of the page above; the HTML and this file carry the same facts. ## Facts - Document number: 2026-19654 - Title: Naveed Aslam: Final Debarment Order - Type: Notice - Agencies: Health and Human Services Department; Food and Drug Administration - Citation: 91 FR 60961 - Published: 2026-09-25 - Effective: 2026-09-25 - Comments close: not stated - Significant: no - Touches household money: yes - Regulation identifier numbers: none - Last updated: 2026-10-02 ## In one line Doc Aslam booted forever from FDA drug dealings ## Summary The FDA has permanently banned Dr. Naveed Aslam from working with any drug companies because he was convicted of a serious crime related to drug regulations. He didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on September 25, 2026. Dr. Aslam can apply to end this ban anytime, but it won’t be easy or quick. ## Abstract The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Naveed Aslam from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Dr. Aslam was convicted of a felony under Federal law for conduct that relates to the regulation of a drug product under the FD&C Act. Dr. Aslam was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of July 9, 2026 (30 days after receipt of the notice), Dr. Aslam has not responded. Dr. Aslam's failure to respond and request a hearing constitutes a waiver of Dr. Aslam's right to a hearing concerning this matter. ## Effects PRIA read - Permanent ban on Dr. Aslam: cost, high. Dr. Naveed Aslam is permanently barred from providing services in any capacity to any person that has an approved or pending drug product application. The debarment is effective September 25, 2026, following his federal conviction on November 17, 2025. - Employers face penalties if they hire him: cost, medium. Any person with an approved or pending drug product application who knowingly employs, retains as a consultant or contractor, or otherwise uses Dr. Aslam's services during his debarment will be subject to civil money penalties under section 307(a)(6) of the FD&C Act. The prohibition and penalty exp… - Dr. Aslam personally liable for penalties if he works: cost, medium. If Dr. Aslam provides services in any capacity to a person with an approved or pending drug product application during his debarment, he will be subject to civil money penalties under section 307(a)(7) of the FD&C Act. This penalty exposure applies during the debarment period that is effective Sept… - FDA will not review his ANDA submissions: cost, medium. During his debarment, the FDA will not accept or review any abbreviated new drug application (ANDA) submitted by Dr. Aslam, except when submitted in connection with an audit under section 306(c)(1)(B) of the FD&C Act. This restriction is effective September 25, 2026. - Can apply to end debarment; application posted publicly: benefit, low. Dr. Aslam may apply at any time for special termination of debarment under section 306(d)(4) of the FD&C Act. Applications submitted electronically to https://www.regulations.gov will be posted publicly, while paper submissions can include a confidential copy to keep certain information from public… ## Related documents - [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11 - [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13 - [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29 - [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25 - [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27 - [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09 ## Sources - [2026-19654 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/25/2026-19654/naveed-aslam-final-debarment-order) - [2026-19654 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-25/pdf/2026-19654.pdf) ## Related - [Previous: 2026-19651, 60-Day Notice of Proposed Information Collection: 2027 Rental Housing Finance S…](https://policyrisk.com/federal-register/2026-19651) - [Next: 2026-19655, Jeffrey Thies: Final Debarment Order](https://policyrisk.com/federal-register/2026-19655) - [All Federal Register documents](https://policyrisk.com/federal-register) Source: PRIA, https://policyrisk.com/federal-register/2026-19654 (as of 2026-10-02).